Wuxi Biologics Ireland Limited

Other

Wuxi Biologics (shanghai) Co., Ltd.

Wuxi Biologies Ireland Limited

Wuxi Biologies (shanghai) Co., Ltd.

Wuxi Biologics Co. Ltd.

Zhisheng Chen

Yong Sen Zheng

Jing Li

Yong Zheng

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

Anti-PD-L1 antibodies

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function

Anti-PD-1 antibodies

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

Growing community of inventors

Shanghai, China

Zhisheng Chen